MD Biosciences Blog

MD Biosciences Releases Tamm-Horsfall (Uromodulin) ELISA

Posted by Amy Clausen on Jul 6, 2009 1:14:00 PM


MD Biosciences, a global biotechnology company, announces the recent launch of its new Tamm-Horsfall (THP, Uromodulin) ELISA. To date, very few manufactured ELISAs are commercially available for the measurement of THP, causing researchers to spend extra time optimizing and manufacturing their own with the potential for variable results. The MD Biosciences Tamm-Horsfall ELISA kit has been optimized during development to provide precise and reproducible results. Selection of antibody pairs, careful control of microplate coating, formulation of reagents and protocol design along with stringent quality control procedures compile a completed ELISA kit that provides researchers a rapid and easy to use alternative to the do-it-yourself methods.

 

Tamm-Horsfall ELISA Specifications (Catalog # M036020):

Range of Assay: 9.375 – 150 ng/mL

Sensitivity: <5.50 ng/mL

Length of Assay: 2 hours 40 min

Sample Size: 50 uL

Precision: < 12.2 %CV for intra- and inter-assay precision

Cross-Reactivity: Human and canine urine samples

 

Tamm-Horsfall protein (THP, also known as uromodulin) is the most abundant protein found in the urine of mammals. THP is 616 amino acids in length with a molecular weight of 80 kDa, and is synthesized in the thick ascending loop of Henle. While the specific function of THP is unknown, it appears to have a role in the regulation of salt and water excretion by the kidney. Soluble THP has been found to help protect against urinary tract infections of E. coli and P. mirabilis by inhibiting the binding of the bacteria to the epithelial cells of the urinary tract. In addition, it has been suggested that THP may help prevent renal stone formation. Defects in THP are associated with human diseases such as familial juvenile hyperuricemic nephropathy (FJHN) and medullary cystic kidney disease (MCKD2).

About MD Biosciences

MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

 

###

 

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.